Expanding the universe of druggable targets
Novel Therapeutics Enabled by Engineering ARRDC1-Mediated Microvesicles
Novel technology, new treatment opportunities
Vesigen’s patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), can be used to precisely deliver a wide range of payloads, including gene editing complexes, proteins, and RNAs to a unique set of tissue and cell types. Vesigen has demonstrated highly efficient in vitro and in vivo functional delivery of payloads across multiple cell types and is committed to developing transformative medicines that address current unmet needs.
Repurposing inter-tissue communication to develop new therapies
ARMMs are a natural communication system used by cells to transfer signals. Vesigen has developed approaches to engineer ARMMs to relay therapeutic payloads to target cells while avoiding endosomal/lysosomal processing and degradation, and to take full advantage of the properties of human extracellular vesicles, such as low immunogenicity and toxicity.
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
